Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?

Stack JP, Moslehi J, Sayed N, Wu JC
Eur Heart J. 2019 40 (22): 1764-1770

PMID: 29377985 · PMCID: PMC6554650 · DOI:10.1093/eurheartj/ehx811

Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies. Promising results with hiPSC-CM chemotherapy studies are raising hopes for improving cancer therapies through personalized medicine and safer drug development. Here, we review the cardiotoxicity profiles of common chemotherapeutic agents as well as efforts to model them in vitro using hiPSC-CMs.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email:

MeSH Terms (14)

Animals Antineoplastic Agents Cardiomyopathies Cardiotoxicity Cardiotoxins Drug Evaluation, Preclinical Genomics Genomics Humans Induced Pluripotent Stem Cells Mice Models, Biological Neoplasms Precision Medicine

Connections (1)

This publication is referenced by other Labnodes entities: